Horrell Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Horrell Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.78K	Hold	24	–	–	﹤0.01%	156
2026 Q1	$4.54K	Hold	24	–	–	﹤0.01%	160
2025 Q4	$4.08K	Hold	24	–	–	﹤0.01%	161
2025 Q3	$3.16K	Hold	24	–	–	﹤0.01%	170
2025 Q2	$2.55K	Hold	24	–	–	﹤0.01%	175
2025 Q1	$2.98K	Hold	24	–	–	﹤0.01%	169
2024 Q4	$3K	Hold	24	–	–	﹤0.01%	194
2024 Q3	$3K	Sell	24 -12	-33%	-$1.31K	﹤0.01%	194
2024 Q2	$4K	Hold	36	–	–	﹤0.01%	194
2024 Q1	$4K	Hold	36	–	–	﹤0.01%	198
2023 Q4	$4K	Hold	36	–	–	﹤0.01%	194
2023 Q3	$5K	Hold	36	–	–	﹤0.01%	187
2023 Q2	$4K	Hold	36	–	–	﹤0.01%	189
2023 Q1	$5K	Hold	36	–	–	﹤0.01%	187
2022 Q4	$6K	Hold	36	–	–	﹤0.01%	181
2022 Q3	$5K	Hold	36	–	–	﹤0.01%	181
2022 Q2	$6K	Hold	36	–	–	﹤0.01%	172
2022 Q1	$6K	Buy	+36	New	+$5.22K	﹤0.01%	179
2021 Q4	–	Sell	-36	Closed	-$5K	–	202
2021 Q3	$5K	Hold	36	–	–	﹤0.01%	175
2021 Q2	$6K	Buy	+36	New	+$6.24K	﹤0.01%	174

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Horrell Capital Management's JAZZ Position: Q2 2026 in Review

Horrell Capital Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 24 shares worth $5.78K. The position accounts for ﹤0.01% of the portfolio, ranked #156.

Horrell Capital Management first reported a position in JAZZ in Q2 2021 and has held it in 20 quarters since. The position peaked at $6K in Q4 2022. 69 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Horrell Capital Management held 24 shares of Jazz Pharmaceuticals worth $5.78K as of Q2 2026.
Horrell Capital Management left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Horrell Capital Management's portfolio in Q2 2026, its #156 holding.
Horrell Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
Horrell Capital Management's Jazz Pharmaceuticals position peaked at $6K in Q4 2022.
69 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Horrell Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.